The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson's disease
- PMID: 40481012
- PMCID: PMC12144259
- DOI: 10.1038/s41598-025-02672-x
The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson's disease
Abstract
This study aimed to evaluate the diagnostic potential of combining 18F-FDG PET and susceptibility-weighted imaging (SWI) to assess cerebral glucose metabolism and iron deposition patterns in Parkinson's disease (PD), and to determine their correlations with clinical progression and diagnostic accuracy. Forty-nine PD patients and 70 age-/sex-matched healthy controls underwent standardized 18F-FDG PET and SWI. Metabolic activity (SUVR) and SWI phase values were quantified in cortical/subcortical regions. Statistical analyses included Mann-Whitney U tests, Pearson/Spearman correlations, and ROC curve analysis to evaluate biomarker-clinical relationships and diagnostic performance. PD patients exhibited hypometabolism in frontal, parietal, and temporal cortices (P < 0.05) and hypermetabolism in the putamen, globus pallidus, and cerebellum (P < 0.05). Cortical hypometabolism correlated with Hoehn-Yahr (H-Y) stages (e.g., temporal lobe: r = - 0.405, P = 0.004) and UPDRS III scores (e.g., frontal cortex: r = - 0.364, P = 0.011). SWI revealed reduced phase values in the substantia nigra, red nucleus, and basal ganglia (P < 0.001), with substantia nigra phase values strongly correlating with H-Y stages (r = - 0.525) and UPDRS III scores (r = - 0.446). Multimodal integration of 18F-FDG PET and SWI achieved superior diagnostic accuracy (AUC = 0.844) compared to single-modality models (PET: AUC = 0.777; SWI: AUC = 0.780, P < 0.0001). The integration of 18F-FDG PET and SWI enhances PD diagnosis by capturing complementary metabolic and iron deposition biomarkers. Cortical hypometabolism may precede subcortical iron accumulation, aligning with Braak staging theory. Limitations include cross-sectional design and technical constraints in SWI quantification. Future studies should validate these findings with longitudinal cohorts and advanced techniques like QSM.
Keywords: 18F-FDG PET; Diagnostic accuracy; Iron deposition; Multimodal biomarkers; Parkinson’s disease; Susceptibility-weighted imaging.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures






Similar articles
-
The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: correlation with 18F-flurodeoxyglucose positron-emission tomography.Neurosci Lett. 2015 Jan 1;584:296-301. doi: 10.1016/j.neulet.2014.10.046. Epub 2014 Nov 4. Neurosci Lett. 2015. PMID: 25450142
-
Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI.Eur Rev Med Pharmacol Sci. 2014;18(18):2605-8. Eur Rev Med Pharmacol Sci. 2014. PMID: 25317792
-
Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.Hum Brain Mapp. 2022 Aug 15;43(12):3735-3744. doi: 10.1002/hbm.25880. Epub 2022 Apr 26. Hum Brain Mapp. 2022. PMID: 35471638 Free PMC article.
-
[18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].Nihon Rinsho. 1997 Jan;55(1):222-6. Nihon Rinsho. 1997. PMID: 9014454 Review. Japanese.
-
Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review.Neurol India. 2020 Mar-Apr;68(2):278-281. doi: 10.4103/0028-3886.284377. Neurol India. 2020. PMID: 32415005
Cited by
-
Ferroptosis in central nervous system injuries: molecular mechanisms, diagnostic approaches, and therapeutic strategies.Front Cell Neurosci. 2025 Jul 22;19:1593963. doi: 10.3389/fncel.2025.1593963. eCollection 2025. Front Cell Neurosci. 2025. PMID: 40766185 Free PMC article. Review.
References
-
- Li, L. et al. A Mendelian randomization study on association of alpha-synuclein and GPNMB with Parkinson’s disease risk and progression. Mol. Neurobiol.10.1007/s12035-025-04928-z (2025). - PubMed
-
- Jankovic, J. & Tan, E. K. Parkinson’s disease: Etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry91, 795–808. 10.1136/jnnp-2019-322338 (2020). - PubMed
MeSH terms
Substances
Grants and funding
- 2024fzyx020/Hubei Province Key Laboratory of Molecular Imaging
- 2024fzyx020/Hubei Province Key Laboratory of Molecular Imaging
- 2024fzyx020/Hubei Province Key Laboratory of Molecular Imaging
- 2024fzyx020/Hubei Province Key Laboratory of Molecular Imaging
- XYY2025QN09/Institution-Level Science and Technology Innovation Project
LinkOut - more resources
Full Text Sources
Medical